{"task_id": "832b887f170f0fe3", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 199/905)", "text": " aff ected side, p749, p815. Management: See p815.\n\n--- Page 205 ---\n191\nChest medicine\nOral alternatives to warfarin (dabigatran, rivaroxaban, apixaban, edoxaban) have \nbeen available for treatment of PE since NICE approval in 2012. They have a rapid \nonset of action (without the need for LMWH overlap) and can be administered in \n\ufb01 xed doses without the need for continuous monitoring. Monitoring is required \nto assess compliance, side eff ects (eg bleeding), and presence of VTE. Antidotes \nfor DOACS are becoming available and in the USA idarucizumab is already licensed.\nDirect oral anticoagulants (DOACS)\nDiagnosis of PE is improved by adopting a stepwise approach, combining an objec-\ntive probability score, with subsequent investigations, as follows.\nAssess the clinical probability of a PE: Many systems exist and one of the most \nfrequently used is the modi\ufb01 ed Wells Criteria (table 4.8).\nTable 4.8 Modi\ufb01 ed two-level PE Wells score\nFeature\nScore\nClinical signs and symptoms of DVT (leg pain and pain on deep palpation \nof veins)\n3\nHeart rate >100 beats per minute\n1.5\nRecently bed-ridden (>3 days) or major surgery (<4 weeks)\n1.5\nPrevious DVT or PE\n1.5\nHaemoptysis\n1\nCancer receiving active treatment , treated in last 6/12, palliative\n1\nAn alternative diagnosis is less likely than PE\n3\nScore <4 = PE unlikely; score >4 = PE likely\nWells PS, Anderson DR, Rodger M, et al. \u2018Derivation of a Simple Clinical Model to Categorize Patients \nProbability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer\u2019. \nThromb Haemost 2000; 83: 416\u201320. \nInvestigating suspected PE\nFig 4.16 Investigation and management of PE.\nPE suspected\nCalculate modi\ufb01 ed Wells score\nScore >4: immediate CTPA or treat \nempirically (LMWH) if delay\nScore <4: do D-dimer\nLength of treatment\n  \n\u2022 Provoked: 3 months and then reassess risk to bene\ufb01 t pro\ufb01 le \n(depends on whether risk factor persists)\n  \n\u2022 Unprovoked: treatment is usually continued for >3 months (people \nwith no identi\ufb01 able risk factor)\n  \n\u2022 Malignancy: continue treatment with LMWH for 6 months or until \ncure of cancer\n  \n\u2022 Pregnancy: LMWH is continued until delivery/end of pregnancy\nD dimer +ve: immediate CTPA \nor empiral treatment LMWH\nD-dimer \u03a9ve: consider \nalternative diagnosis", "text_length": 2263, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 199/905)", "type": "chunk", "chunk_index": 198, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.286567", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.287293", "status": "complete", "chunks_added": 2}